Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q8NFJ6

UPID:
PKR2_HUMAN

ALTERNATIVE NAMES:
G-protein coupled receptor 73-like 1; G-protein coupled receptor I5E; GPR73b; GPRg2

ALTERNATIVE UPACC:
Q8NFJ6; A5JUU1; Q2M3C0; Q5TDY1; Q9NTT0

BACKGROUND:
The Prokineticin receptor 2, alternatively named GPR73b or GPRg2, is integral to G(q) protein-coupled signaling pathways. Activation of this receptor results in significant cellular responses, including calcium mobilization and mitogen-activated protein kinase activation.

THERAPEUTIC SIGNIFICANCE:
Given its crucial role in Hypogonadotropic hypogonadism 3, understanding Prokineticin receptor 2 could unlock new therapeutic avenues. Its genetic association with this disorder suggests its potential as a target for interventions aimed at correcting hormonal and sensory deficits.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.